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Abstract
Background: Methylene diphenyl diisocyanate (MDI), a reactive chemical used for commercial polyurethane
production, is a well-recognized cause of occupational asthma. The major focus of disease prevention efforts to
date has been respiratory tract exposure; however, skin exposure may also be an important route for inducing
immune sensitization, which may promote subsequent airway inflammatory responses. We developed a murine
model to investigate pathogenic mechanisms by which MDI skin exposure might promote subsequent immune
responses, including respiratory tract inflammation.
Methods: Mice exposed via the skin to varying doses (0.1-10% w/v) of MDI diluted in acetone/olive oil were
subsequently evaluated for MDI immune sensitization. Serum levels of MDI-specific IgG and IgE were measured by
enzyme-linked immunosorbant assay (ELISA), while respiratory tract inflammation, induced by intranasal delivery of
MDI-mouse albumin conjugates, was evaluated based on bronchoalveolar lavage (BAL). Autologous serum IgG
from “skin only” exposed mice was used to detect and guide the purification/identification of skin proteins
antigenically modified by MDI exposure in vivo.
Results: Skin exposure to MDI resulted in specific antibody production and promoted subsequent respiratory tract
inflammation in animals challenged intranasally with MDI-mouse albumin conjugates. The degree of (secondary)
respiratory tract inflammation and eosinophilia depended upon the (primary) skin exposure dose, and was maximal
in mice exposed to 1% MDI, but paradoxically limited in mice receiving 10-fold higher doses (e.g. 10% MDI). The
major antigenically-modified protein at the local MDI skin exposure site was identified as albumin, and
demonstrated biophysical changes consistent with MDI conjugation.
Conclusions: MDI skin exposure can induce MDI-specific immune sensitivity and promote subsequent respiratory
tract inflammatory responses and thus, may play an important role in MDI asthma pathogenesis. MDI conjugation
and antigenic modification of albumin at local (skin/respiratory tract) exposure sites may represent the common
antigenic link connecting skin exposure to subsequent respiratory tract inflammation.
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Isocyanates, the reactive chemicals used in the produc-
tion of polyurethane foams, coatings, and adhesives
remain a leading cause of occupational asthma world-
wide, despite substantial efforts at disease prevention
[1]. MDI has become the most commonly used isocya-
nate for multiple reasons, including its relatively low
volatility at room temperature, which has been pre-
sumed to make it “safer” than other major isocyanates,
e.g. hexamethylene and toluene diisocyanate (HDI and
TDI respectively) [2,3]. However, respirable forms of
MDI are inherent to its common applications, which
often involve heating and/or spraying the chemical, thus
creating vapor and aerosols. The number of people at
risk from MDI exposure continues to increase with
increasing demand for polyurethane containing pro-
ducts; for example, “environmentally-friendly” or “green”
construction using MDI-based spray-foam insulation
made with soybean (vs. petroleum)-derived polyols
[2,4,5]. A better understanding of MDI asthma patho-
genesis is central to multiple approaches toward protect-
ing the health of occupationally exposed individuals,
including hygiene, engineering controls, personal protec-
tive equipment, exposure/disease surveillance and treat-
ment [6-9].
Despite decades of research, the pathogenesis of MDI,
and other isocyanate (TDI, HDI)-induced asthma
remains unclear; however, contemporary theories suggest
one important step involves the chemical’s reactivity with
“self” proteins in the respiratory tract, causing antigenic
changes in their structure/conformation, which trigger
an immune response [10,11]. The self-proteins crucial to
this process remain incompletely defined, however in ani-
mal models, the major target for isocyanate in the air-
ways has been identified as albumin, by multiple
investigators using several distinct approaches (immuno-
chemical, radiotracing) [12-15]. Albumin has also been
f o u n dc o n j u g a t e dw i t hi s o c y a nate in vivo in occupation-
ally exposed humans, and is the only known “carrier”
protein for human antibody recognition and binding (e.g.
IgE/IgG from exposed individuals specifically bind to iso-
cyanate conjugates with human albumin, but not other
proteins) [16]. Furthermore, in animal models of TDI
and HDI asthma, albumin conjugates have been shown
to induce asthma-like airway inflammation and/or phy-
siologic responses in previously (isocyanate) sensitized
animals [17-22]. Thus, while the pathogenesis of MDI
(and other isocyanate-induced) asthma remains unclear,
previous studies support an important role for chemical
conjugation with albumin present in the airways.
Given the airway localization of inflammation in iso-
cyanate asthma patients, inhalation was originally
assumed to be the primary exposure route responsible
for the immune activation associated with exposure.
However, evidence continues to increase in support of
an alternative hypothesis; that skin exposure is equally
(if not more) effective for isocyanate immune sensitiza-
tion. Skin exposure to isocyanates is relatively common
during polyurethane production (likely more common
than airway exposure for “low volatility” isocyanates
such as MDI) and thus could play a major role in sensi-
tizing workers, despite appropriate respiratory tract pro-
tection, and without “warning” (methods for monitoring
skin exposure remain poorly developed, and skin reac-
tions are rare). Once immune sensitization to isocyanate
occurs, extremely low airborne levels (below OSHA
established permissible exposure levels) can trigger asth-
matic reactions [23,24]. Thus, while research, practice
and regulation have focused almost exclusively on
understanding and preventing inhalation exposures
[6,25-27], skin exposure may be an equally critical, yet,
under-recognized target for isocyanate asthma preven-
tion [6,8,28,29].
In this study, we developed a murine model to investi-
gate the capacity of MDI skin exposure to induce sys-
temic immune sensitization, and to identify key “MDI
antigens” in this process. The investigation builds upon
previous studies in guinea pigs and rats, which pio-
neered the hypothesis that isocyanate skin exposure
might promote airway inflammation/asthma [30-33].
The investigation also builds upon more recent mouse
models of HDI and TDI asthma, which developed tech-
niques for effectively delivering isocyanates (as mouse
albumin conjugates) to the lower airways; thus overcom-
ing technical challenges imposed by species difference
between humans and mice ("scrubbing” action of nasal
cavities and obligatory nasal breathing of mice), as well
as respiratory tract irritation/toxicity by organic solvents
(acetone, toluene) typically used for diluting isocyanate
[15,22,31,34-37]. The findings of the present study are
discussed in the context of disease (MDI asthma) patho-
genesis and prevention.
Materials and methods
Reagents
Mouse and bovine albumin, triton X-100, sodium chlor-
ide, dithiothreitol (DTT), MDI, protease inhibitor cock-
tail and Tween 20 were from Sigma (St. Louis, MO).
Urea and Tris-HCl were from American Bioanalytical
(Natick, MA). Nonidet P40 substitute (Igepal CA-360)
was from USB Corporation (Cleveland, OH). Acetone
was from J.T. Baker (Phillipsburg, NJ). Ethylenediamine-
tetraacetic acid (EDTA) and phosphate buffered saline
(PBS) were from Gibco (Grand Island, NY). Nunc Maxi-
sorp™ microtiter plates were obtained through VWR
International (Bridgeport, NJ). SuperSignal West Femto
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strate was obtained through Thermo Fisher Scientific
(Rochester, NY). Tetramethylbenzidine (TMB) substrate
was from BD Bioscience (San Jose, CA). Streptavidin
conjugated alkaline phosphatase and p-nitrophenyl
phosphate (pNPP) substrate were from Kirkegaard &
Perry Laboratories (Gaithersburg, MD). Peroxidase con-
jugated rat anti-mouse anti-IgG1,a n da n t i - I g G 2a were
from Pharmingen (San Diego, CA). Protein G Sepharose
4 Fast Flow was from GE Healthcare (Piscataway, NJ).
Biotin-labeled rat anti-mouse IgE was from BioSource
International, Inc. (Camarillo, CA). Imperial protein
stain and rabbit anti-mouse IgG were from Pierce
(Rockford, IL). Nitrocellulose and reducing gel electro-
phoresis buffer were from Bio-Rad (Hurcules, CA). Rab-
bit anti-tropomyosin, rabbit anti-collagen type 1/a2, and
mouse anti-cytokeratin 14 were from Santa Cruz Bio-
technology, Inc (Santa Cruz, CA).
Animals and skin sensitization
Female BALB/c mice, 9 to 12 weeks, from the National
Cancer Institute (Frederick, MD), were used in all experi-
ments. The backs of mice were shaved with electric clip-
pers 1 day before exposure to 50 μlo fM D Ir a n g i n gi n
dose from 0.1%-10% weight/volume (w/v), delivered in a
4:1 acetone/olive oil “vehicle” (approximate surface area
0.5 - 1 cm
2 on right side). Control mice were identically
exposed to 50 μL of an acetone/olive oil mixture without
MDI. Mice were anesthetized during the skin exposure,
and 20 minutes after application, the exposed area was
cleansed with 70% ethanol. Mice were re-exposed a sec-
ond time 7 days later on the opposite (left) side of their
back. Serum of exposed mice was obtained on day 21
a n da n a l y z e db yE L I S Af o rM D I - s p e c i f i ca n t i b o d i e s ,a n d
used as a probe to detect MDI (exposure)-induced anti-
genic-modification of “self” mouse skin proteins. In some
studies MDI skin exposed mice were subsequently
exposed to MDI-albumin conjugates via the respiratory
tract (see below). A time line of skin/airway exposures
and sample acquisition is shown in Figure 1.
Measurement of serum antibodies
Mouse sera samples were analyzed for MDI-specific antibo-
dies using an enzyme-linked immunosorbant assay (ELISA),
similar to that our laboratory has recently developed for
measuring MDI-specific human antibodies [38]. Microtiter
plates were coated with 1 μg/well of mouse albumin conju-
gated with MDI (see below), or control “mock exposed”
mouse albumin, by overnight incubation at 4°C, in 0.1 M
carbonate buffer (pH 9.5). Plates were “blocked” with 3%
(w/v) bovine serum albumin before murine serum samples
were titrated in blocking buffer. Sera were incubated for 1
hour at 25°C, followed by a 1:2000 dilution of peroxidase
conjugated rat anti-mouse anti-IgG1 or anti-IgG2a. MDI-
specific IgE was detected with biotin-labeled secondary rat
anti-mouse IgE, followed by streptavidin-conjugated alka-
line phosphatase. ELISAs were developed with TMB or p-
NPP substrate and optical density (OD) measurements
were obtained on a Benchmark microtiter plate reader from
Bio-Rad. All samples were tested in triplicate to obtain aver-
age values expressed in figures.
MDI-specific IgG data are reported as end-titers; the
reciprocal of the highest dilution that yields a positive
OD reading, > 3 S.D. units above control serum from
unexposed mice. Isocyanate-specific IgE data are repre-
sented as a binding ratio, as recommended in previous
clinical studies, which is calculated as the (OD of wells
coated with MDI-albumin) ÷ (OD of wells coated with
control albumin) [39]. Total serum IgE levels were mea-
sured as previously described [40].
MDI-albumin
MDI-mouse albumin conjugates used for ELISA and
respiratory tract challenge were prepared under the
Figure 1 Experimental time line. The major time points of dermal and/or subsequent airway exposure as well as sample acquisition are
depicted.
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antigenic MDI-conjugates with human albumin [38].
Mouse albumin in phosphates buffered saline (pH 7.2)
at 5 mg/ml was mixed with a freshly prepared solution
of 10% (w/v) MDI dissolved in acetone, to achieve a
final MDI concentration of 0.1% (w/v). The reaction
mixture was rotated end-over-end for 2 hours at room
temperature, dialyzed against PBS and (0.2 μM) filtered.
“Mock exposed” albumin was identically prepared, using
only acetone (1% v/v final concentration) for the 2-hr
exposure period. MDI conjugation to mouse albumin
was verified based on characteristic shift in electro-
phoretic mobility, and absorbance at 250 nm, due to
MDI’s double ring structure [41]. In later experiments,
for comparative purposes (with albumin purified from
skin exposed to MDI in vivo, see below), we generated
MDI-mouse albumin conjugates in vitro with varying
levels of MDI/protein molecule, by varying the MDI
concentration during conjugation reactions.
Respiratory Tract Challenge with MDI-mouse albumin
conjugates
Mice were lightly anesthetized with methoxyflurane and
exposed to 50 μL of a 2 mg/ml solution of MDI-albu-
min or control “mock exposed” albumin in PBS by
means of an intranasal droplet on days 14, 15, 18, and
19; and sacrificed by means of CO2 asphyxiation on day
21. Bronchoalveolar lavage (BAL) cell counts and differ-
entials were performed as previously described [40].
Processing of skin proteins
Mice were skin exposed to MDI or vehicle for 20 min-
utes, as described above; following which, the exposed
area was wiped clean with 70% ethanol, surgically
excised, and snap frozen in liquid nitrogen. Skin samples
were then homogenized in a glass tissue grinder in an
isotonic, pH buffered, detergent solution (20 mM Tris-
HCl, 0.15 M NaCl, 1 mM EDTA, 1% Triton X-100, 0.5%
Nonidet P40 and a cocktail of protease inhibitors). The
homogenized samples were then microfuged at 16,000 x
g for 5 minutes to obtain a “detergent soluble” fraction
(supernatant) of skin proteins. Before Western blot analy-
sis, detergent extracted skin samples were depleted of
endogenous murine immunoglobulins by incubation with
Protein G-coated sepharose beads, and clearance by cen-
trifugation. The detergent insoluble fraction of skin sam-
ples was further homogenized in a strong denaturing
buffer containing 9M urea and 50 mM DTT, to obtain a
urea soluble fraction of skin proteins.
Detection of antigenically modified skin proteins (MDI
antigens)
Skin samples from MDI exposed mice were Western
blotted with serum IgG from autologous mice that had
been “skin-only” exposed to MDI, to detect “self” pro-
teins antigenically modified by MDI exposure. Specificity
controls included parallel blots with sera from mice
exposed to vehicle only, and irrelevant (anti-ovalbumin)
hyperimmune sera. Electrophoresis and Western blot
were performed as previously described using pre-cast
sodium dodecyl sulfate (SDS) acrylamide gels (4-15%
gradient) from BioRad, and nitrocellulose membrane
[42,43]. Nitrocellulose strips were incubated for 2 hrs
with a 1:100 dilution of sera, washed extensively with
PBS containing 0.05% Tween 20, incubated with a
1:2000 dilution of peroxidase conjugated anti-mouse
IgG, and developed with enhanced chemiluminescence
substrate.
Purification of “MDI antigens” from exposed skin
Proteins from MDI exposed mouse skin were purified
b ya2 - s t e p( i s o e l e c t r i cf o c u s ing/electroelution) process,
guided by serum IgG from “skin only” exposed autolo-
gous mice, to detect antigenic modification. Preparative
isoelectric focusing was performed using a Rotofor
® sys-
tem from Bio-Rad, according to the manufacturers
recommendations, to initially separate skin proteins into
20 fractions between pH 3 and 10, with subsequent re-
focusing between pH 3 to 6, to increase resolution.
Rotofor fractions containing proteins antigenically modi-
fied by MDI exposure were further fractionated and
analyzed by parallel Western blot/SDS-PAGE, from
w h i c ht h e yw e r ee x c i s e du s i n gaB i o - R a dM o d e l4 2 2
Electro-Eluter run at constant current (8-10 mA/glass
tube) for 3-5 hrs. Purified proteins were aliquoted and
further analyzed for protein sequence (see below) and
confirmation of MDI-antigenicity via immunoblot with
serum IgG from exposed mice.
Protein identification
Liquid chromatography (LC) followed by tandem mass
spectrometry (MS/MS) was performed by the Yale Keck
Center on a Thermo Scientific LTQ-Orbitrap XL mass
spectrometer, as previously described [44]. Briefly, puri-
fied proteins were reduced and carboxamidomethylated,
trypsin digested and desalted with a C18 zip-tip column
before MS/MS analysis. From uninterrupted MS/MS
spectra, MASCOT compatible files (http://www.
matrixscience.com/home.html) were generated, and
searched against the NCBI non-redundant database
[45,46]. For true positive protein identification, the 95%
confidence level was set as a threshold within the MAS-
COT search engine (for protein hits based on random-
ness search). In addition, the following criteria must also
have been met (1) two or more MS/MS spectra match
the same protein entry in the database searched, (2)
matched peptides were derived from trypsin digestion of
the protein, (3) the peptides be murine in origin, and (4)
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cular weight. The identity of the purified proteins was
further confirmed by Western blots with commercially
available polyclonal or monoclonal antibodies (type I
collagen, keratin-14, and tropomyosin), using hyperim-
mune anti-ovalbumin rabbit or mouse serum as a (nega-
tive) specificity control.
Statistical analyses
Statistical significance was determined using ANOVA
with a block design for pooled data from more than one
experiment. Antibody data, calculated through 2-fold
dilutions, were log(2) transformed for analysis.
Results
Skin exposure induces an MDI-specific antibody (i.e.
systemic) response
The capacity of MDI skin exposure to induce an MDI-
specific antibody response was evaluated through ELISA
analysis of sera from mice exposed to MDI diluted in
acetone, at varying concentrations ranging from 0.1-10%
weight/volume (w/v). We found that skin exposure to ≥
1% MDI resulted in the development of high serum
levels of MDI-specific antibodies. As shown in Figure 2,
the end titers for MDI-specific antibody reached
>1:100,000 and >1:30,000 for IgG1 and IgG2a subclasses
respectively. MDI-specific IgE and total IgE serum levels
were also elevated, up to 6-fold above control levels.
The IgG and IgE induced by MDI skin exposure did not
bind to unexposed proteins, or other reactive chemical
“haptens” such as DNCB or adipoyl chloride (not
shown).
Influence of skin exposure on (secondary) respiratory
tract exposure
Mice initially exposed to MDI via the skin, were subse-
quently exposed via the respiratory, to a water soluble
derivative of MDI (mouse albumin conjugates), in an
adaptation of our murine HDI asthma model [22]. In
the present experiments, mice that received only vehicle
(acetone/olive oil) skin exposure, exhibited no change in
bronchoalveolar lavage (BAL) cell numbers or differen-
tials, when (airway) challenged with MDI-albumin con-
jugates. However, mice with previous (≥1%) MDI skin
exposure developed significant airway inflammatory
responses to respiratory challenge. The observed
increase in total cell numbers of BAL samples (obtained
48 hours post exposure) was primarily due to increases
in eosinophils and lymphocytes (Figure 3). Thus,
respiratory tract exposure, to concentrations of MDI
(albumin conjugates) that normally do not evoke cellular
inflammation, causes pathologic changes (increased
number of airway cells with Th2-profile) in mice pre-
viously exposed to MDI via the skin.
The initial MDI (skin) exposure dose was found to
have a strong affect on the level of airway inflammation
subsequently induced by respiratory tract challenge. The
largest degree of airway inflammation was observed in
Figure 2 Serum antibody responses to MDI skin exposure. BALB/c mice were skin (only) exposed to vehicle (acetone/olive oil) or varying
concentrations of MDI (0.1 - 10% w/v) as shown on X-axis. On day 21, serum levels of MDI-specific IgG1/IgG2a (inverse end-titer), IgE binding
(ratio) and total IgE (ng/ml) were measured. Data shown are the mean ± SEM of 12 mice per group.
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centration, with more limited, albeit significant, inflam-
mation in mice that had been skin exposed to 10% (w/
v). The reason for the paradoxically limited airway
inflammation in mice (skin) exposed to the highest test
dose of MDI (10% w/v) remains unclear; however, ana-
logous findings have been reported in HDI exposed
mice [22]. A similar (non-linear dose-response) phe-
nomenon is well-described for contact sensitization to
many other reactive chemicals, e.g. formaldehyde, picryl
chloride, DNCB [47].
Respiratory tract exposure boosts serum levels of MDI-
specific antibodies elicited by primary skin exposure
In mice with prior MDI skin exposure, subsequent
respiratory tract exposure to MDI-albumin conjugates
was found to boost MDI-immune sensitization, based
on levels of MDI-specific serum IgG and IgE. As shown
in Figure 4, statistically significant increases were detect-
able among Th2-associated subclasses/isotypes, IgG1
and IgE, but not in the Th1-associated subclass, IgG2a.
T h u s ,i nm i c ep r e v i o u s l ye x p o s e dt oM D Iv i at h es k i n ,
subsequent respiratory tract exposure to MDI (albumin
conjugates) further boosts MDI immune sensitivity.
Identification of MDI antigens in exposed skin
As shown in Figure 5A, detergent extracts from 1% MDI
exposed skin contained a single antigenically-modified
protein, specifically recognized by antibodies from auto-
logous MDI skin (only) exposed mice, but not control
mouse sera. The “MDI antigen” was purified from
exposed skin by a 2-step process (Figure 5B, and 6A),
and identified as albumin through LC-MS/MS analysis
(see Additional file 1). The antigenically modified albu-
min from exposed skin exhibited biophysical properties
consistent with MDI conjugation, when compared with
Figure 3 Airway inflammatory responses to MDI in mice sensitized via skin exposure.B A L B / cm i c et h a tw e r ei n i t i a l l ys k i ne x p o s e dt o
vehicle or varying doses of MDI were subsequently exposed via the respiratory tract as described. On day 21, the number of cells recovered (by
BAL) was determined. The data shown, are the mean ±SEM of 12 mice per group; *(p < .005) and
#(p < .05) compared to all other groups.
Figure 4 Respiratory tract exposure boosts serum levels of MDI-specific antibodies elicited by primary skin exposure. Serum levels of
MDI-specific antibodies from mice (with (+) or without (-) prior skin exposure) following respiratory tract exposure to MDI albumin conjugates
(+) or mock exposed albumin (-). Each bar represents the mean ± SEM for 12 mice; * p < .001 comparing skin exposed vs. skin + airway
exposed.
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MDI-mouse albumin conjugates prepared in vitro; speci-
fically, alterations in electrophoretic migration and
change in absorbance at 250 nm (Figure 6A&6B).
Additional “MDI antigens”, specifically recognized by
antibodies from MDI skin (only) exposed autologous
mice, but not control mouse sera, were detectable in
urea extracts from skin exposed to the highest test dose
of MDI (10%), as shown (Figure 7A). Among these anti-
genically-modified proteins, the most prominent, based
on recognition by serum IgG from skin exposed autolo-
gous mice, were purified through elecrophoretic fractio-
nation methods, and identified by LC-MS/MS as pro-
collagen type 1/a2, keratin 14, and tropomyosin (see
Additional file 1). Their (MDI) antigenicity and identity
were further confirmed by Western blot with autologous
serum IgG from skin exposed mice (Figure 7B) and
commercially available protein-specific (collagen, kera-
tin, tropomysosin) antibodies (not shown).
Discussion
In the present study, we utilized a murine MDI expo-
sure model to demonstrate the capacity of skin exposure
to induce immune sensitization to MDI, and promote
airway inflammation upon subsequent respiratory tract
exposure. The degree of secondary (respiratory tract)
inflammation was found to depend upon the primary
(skin) exposure dose, and exhibited a non-linear
Figure 5 Detection and fractionation of the major MDI antigen in detergent extracts of exposed skin. (A) Proteins from (-) control or (+)
1% MDI exposed mouse skin, were separated by SDS-PAGE and stained with commassie blue or Western blotted with autologous sera from
MDI skin exposed mice (lanes 3 and 4) or control mice (lanes 5 and 6). Arrow highlights major antigenic protein from exposed skin, with
apparent shift in migration, indicating change in conformation/charge. (B) The MDI antigen, highlighted by arrows, was separated from other
skin proteins by isoelectric focusing. Shown is Ponceau S protein staining of Rotofor
® fractions 2-16 after SDS-PAGE and transfer to nitrocellulose
membrane. Lanes 1 and 17 contain prestained molecular weight markers.
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to 1% (w/v) MDI, and was paradoxically limited at 10-
fold higher (skin) exposure doses; a phenomenon similar
to that reported for HDI. Albumin in exposed skin was
found to undergo antigenic as well as structural/confor-
mational changes, consistent with MDI conjugation.
Furthermore, MDI-mouse albumin conjugates were spe-
cifically recognized by serum IgE and IgG, and triggered
heightened respiratory tract responses, in previously
skin exposed mice. The data highlight mechanisms by
which MDI skin exposure might contribute to the
development of systemic immune sensitization and pos-
sibly MDI asthma.
The present findings are consistent with limited
reports on MDI skin exposure in mice, despite differ-
ences in exposure protocols, and methods of assessing
immunologic responses [48-51]. The findings are also
consistent with data on the smaller, more volatile 6-car-
bon isocyanates, HDI and TDI, including, the non-linear
“(skin) dose/(respiratory tract) response” and mixed
Th1/Th2-like response to skin exposure [22,31,34,36,52].
Importantly, in all of these studies, the isocyanate
Figure 6 Purification of antigenically modified albumin from in vivo exposed mouse skin. (A) SDS-PAGE analysis (top) and Western blot
with serum IgG from skin exposed mice (bottom) of the major MDI antigen (highlighted with *), purified from skin exposed in vivo to (+) 1%
MDI and its corresponding protein purified from (-) control skin (highlighted with #). For comparison, MDI-albumin conjugates prepared in vitro
using varying doses of MDI (0.001%, 0.01% and 0.1%, lanes 4 to 6 respectively) are shown to the right of the molecular weght markers. The MDI
antigen was not recognized using control sera from vehicle expose mice or irrelevant hyperimmune mouse serum (not shown). (B) Ultraviolet
light absorbance spectra of albumin purified from control or 1% MDI exposed skin. (C) For comparison, commercially purified mouse albumin
and MDI-mouse serum albumin conjugates prepared in vitro were similarly analyzed. *Note increase in absorbance in the 250 nm range due to
MDI’s aromatic rings.
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skin exposure (≤%1 w/v) were within the range com-
monly used in polyurethane production, and are likely
experienced by workers in multiple occupational settings
[8,28,53].
The presently described mouse model possesses dis-
tinct strengths as well as limitations compared with pre-
viously published animal studies of MDI and/or other
isocyanate-induced asthma. One major strength is the
use of skin as the primary exposure route for inducing a
state of MDI-specific immune sensitization in which
subsequent respiratory tract exposure leads to asthma-
like inflammation. In this regard, the present investiga-
tion differs from prior studies attempting to model iso-
cyanate-induced airway inflammation through
“respiratory tract only” exposure, which have met lim-
ited success [15,31,49,54-60]. Another strength of the
present study is the use of autologous serum IgG from
skin exposed mice to identify immunologically-relevant
protein targets for MDI conjugation and (antigenic)
modification. The major weakness of the study, as
viewed a priori, was the use of MDI-albumin conjugates,
rather than MDI itself, for respiratory tract exposure
(see Introduction for rationale), thus bypassing a major
step between inhalation and inflammation. Retrospec-
tively, however, the data suggest that albumin conjugates
m a yb eu n i q u e l ys u i t e da sa n t i g e n si nm o d e l i n g
isocyanate asthma, especially secondary to initial skin
exposure.
The data provide new insight into the reactivity of
MDI with proteins present in the skin, which likely con-
tributes to the development of MDI immune sensitiza-
tion. At the 1% MDI exposure dose (which promoted
the strongest secondary respiratory tract responses),
only 1 skin protein, albumin, exhibited changes consis-
tent with MDI conjugation (charge/conformation, ultra-
violet light absorbance, antigenicity). Albumin is a major
protein of the extracellular compartment of the skin,
but has not been previously recognized as a target for
isocyanate at that anatomical location [61]. However,
albumin in airway fluid has been described as a major
target for isocyanate conjugation in vivo following
respiratory tract exposure [12-14,16,43,62]. Furthermore,
albumin is the only known human protein whose conju-
gation with isocyanate confers specific recognition by
human antibodies from exposed individuals [43,63].
Thus, the present data suggest that MDI conjugation to
albumin in exposed skin creates an antigenic trigger
that promotes subsequent airway inflammatory
responses to respiratory tract exposure [22,35].
While albumin was the only MDI antigen detectable
in skin exposed to 1% MDI, additional proteins were
found to be antigenically-modified in skin samples
e x p o s e dt ot h eh i g h e s tt e s td o s e( 1 0 % )o fM D I .T h e
Figure 7 Identification of MDI antigens in urea extracts of exposed skin. (A) The detergent insoluble fraction of (-) control or (+) 10% MDI
exposed skin tissue were further homogenized in 9 M urea, separated by SDS-PAGE, and stained for total proteins (lanes 1 and 2). Parallel
Western blot with sera from autologous MDI skin exposed mice (lanes 3 and 4) vs. control mouse sera (lanes 5 and 6) identified at least three
antigenically modified proteins (MDI antigens) in these samples; see arrows. (B) The MDI antigens from 10% MDI exposed mouse skin were
purified and reanalyzed by protein stain following SDS-PAGE, and parallel Western blot with autologous sera from MDI skin exposed mice.
Arrows highlight antigenically modified collagen (*1), keratin (*2) and tropomyosin (*3) from MDI exposed skin. Actin from unexposed mouse
skin, which was not recognized by autologous sera, was run as a negative control (lane 3). MDI antigens were not detectable using control sera
from vehicle expose mice or irrelevant hyperimmune mouse serum (not shown).
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Page 9 of 12significance of these proteins in response to MDI skin
exposure will require further investigation. However, it
is interesting to speculate the possibility that reactivity
with MDI may alter their normal conformation in a
manner that breaks “immune tolerance” given the
reported association of anti-keratin antibodies with iso-
cyanate asthma, and the pan-allergenicity of non-mam-
malian tropomyosin [64-66].
If the present data translate across species, they will
provide important insight into pathogenic mechanisms
of MDI asthma as well as practical guidance for disease
prevention, among occupationally exposed individuals.
The murine model will facilitate investigation of the role
of specific genes, through transgenic technology, and
provide a system for evaluating the effectiveness of dif-
ferent exposure interventions. The ELISA assay for
MDI-specific IgG, described herein, may be helpful in
assessing workplace skin exposure, which currently goes
largely undetected, due to the lack of practical metho-
dology for measuring. Furthermore, recognition of the
ability to generate systemici m m u n es e n s i t i z a t i o nt o
MDI via skin exposure, may promote increased aware-
ness and use of personal (skin) protection, including
gloves, overalls and head coverings.
Conclusions
In summary, we developed a murine model to investi-
gate the potential consequences of MDI skin exposure,
which is relatively common in the numerous industries
that utilize MDI to make polyurethane products. The
present data demonstrate that MDI skin exposure can
induce systemic immune sensitization and asthmatic-
like inflammatory responses to subsequent respiratory
tract exposure. Albumin was found to be a major target
for MDI conjugation in exposed skin, and MDI-albumin
conjugates were also shown to trigger heightened
respiratory tract inflammation in previously skin
exposed mice (vs. unexposed controls). The data may
help explain the development of new MDI asthma cases
despite extremely low workplace airborne MDI levels
and provide practical guidance for exposure and disease
prevention.
Additional material
Additional file 1: Antigenically modified proteins from exposed
mouse skin identified by LC-MS/MS. A table listing the positively
identified peptides from the purified protein bands specifically
recognized by serum IgG from MDI skin exposed mice.
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